The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. Not only did MariTide fail to outperform Lilly’s Zepbound, but both Lilly and Novo also have next-generation medications under development, with promising data showing even more impressive weight loss results. “A 20% weight loss would have been best-in-class if …
